Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
QuantumLeap Healthcare Collaborative
COVID-19
The goal of this project is to rapidly screen promising agents, in the setting of an
adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase
2 platform design, agents will be identified with a signal suggesting a big impact on
reducing mortality and the need for, a1 expand
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation. Type: Interventional Start Date: Jul 2020 |
|
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Yea1
ModernaTX, Inc.
SARS-CoV-2
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from
Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is
designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to
prevent COVID-19 for up to 2 years afte1 expand
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273. Type: Interventional Start Date: Jul 2020 |
|
Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective1
University of Oklahoma
Coronavirus Infection
Disease Prevention
The purpose of this study is to assess the safety and efficiency of an assembled modified
mask in protecting health care workers against Coronavirus in case of any personal
protective equipment shortage. At least 20 healthy participants will be recruited to try
the modified mask. The modified masks1 expand
The purpose of this study is to assess the safety and efficiency of an assembled modified mask in protecting health care workers against Coronavirus in case of any personal protective equipment shortage. At least 20 healthy participants will be recruited to try the modified mask. The modified masks will be made from masks that are already available as well as filters available in the pulmonary department at the Oklahoma City VA Health Care System Type: Interventional Start Date: May 2020 |
|
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
Medical College of Wisconsin
COVID-19
This is a Phase II study. This research study is being conducted to use convalescent
donor plasma in seriously ill patients who have COVID-19. expand
This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19. Type: Interventional Start Date: May 2020 |
|
Pharmacist Management of Paxlovid eVisits
Kaiser Permanente
COVID-19
Quality of Care
The goal of this cluster randomized trial is to compare two modes of management --
pharmacist care vs. pooled adult and family medicine physician care -- for electronically
submitted requests (e-visits) for Paxlovid by adults with COVID-19. It will compare
quality of care based on counseling for co1 expand
The goal of this cluster randomized trial is to compare two modes of management -- pharmacist care vs. pooled adult and family medicine physician care -- for electronically submitted requests (e-visits) for Paxlovid by adults with COVID-19. It will compare quality of care based on counseling for common potential drug-drug interactions and time to prescription, as well as the time and financial costs of care in the two groups. Type: Interventional Start Date: Oct 2023 |
|
Commercially Available Cannabis Products for Immune Support
Center For Interventional Pain and Spine
Influenza
COVID-19
Common Cold
This study will be a prospective observation of the use of commercially available hemp
and cannabis products marketed for immune support. expand
This study will be a prospective observation of the use of commercially available hemp and cannabis products marketed for immune support. Type: Observational Start Date: Nov 2023 |
|
Variation In Facial Morphology As A Determinant Of Face Covering Performance: FACEFIT
University of North Carolina, Chapel Hill
Healthy
This study examines the role of variations in the dimensions of facial features on the
fitted filtering efficiency of face coverings available to the public during the COVID-19
pandemic. Approximately 100 young (18-55 years old) healthy participants will be
recruited. Exclusionary criteria include1 expand
This study examines the role of variations in the dimensions of facial features on the fitted filtering efficiency of face coverings available to the public during the COVID-19 pandemic. Approximately 100 young (18-55 years old) healthy participants will be recruited. Exclusionary criteria include pregnancy and breastfeeding. After informed consent, participants will enter a chamber where they will undergo 3D facial scanning using a dedicated camera system and be trained to don an N95 respirator properly. The fitted filtering efficiency (FFE) of 4 types of face coverings: a N95 respirator, a KN95 respirator (with and without a clip), a surgical mask (with and without a clip), and a KF94 respirator (with and without a clip) will be tested on each participant using the OSHA quantitative fit testing protocol for filtering face pieces. Type: Observational Start Date: Jun 2022 |
|
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
Duke University
Quality of Life
Injection Site Reaction
Adverse Drug Event
Systemic Reaction
This study is a prospective, randomized clinical trial. During this study, participants
will be randomly assigned to receive quadrivalent inactivated influenza vaccine (IIV4)
and mRNA COVID-19 vaccine either simultaneously or sequentially, 7-14 days apart. Persons
in the simultaneous group will rec1 expand
This study is a prospective, randomized clinical trial. During this study, participants will be randomly assigned to receive quadrivalent inactivated influenza vaccine (IIV4) and mRNA COVID-19 vaccine either simultaneously or sequentially, 7-14 days apart. Persons in the simultaneous group will receive mRNA COVID-19 and IIV4 at Visit 1 (Day 1) and a saline placebo injection at Visit 2. Persons in the sequential group will receive mRNA COVID-19 vaccine and a saline placebo at Visit 1 (Day 1) and IIV4 injection at Visit 2. For participants receiving their primary dose series, a second dose of mRNA COVID-19 vaccine will be administered either 3 to 8 weeks or 4 to 8 weeks following the first dose, depending upon the mRNA COVID-19 vaccine provided. For those receiving a booster dose of mRNA COVID-19 only a single mRNA COVID-19 will be received in this study. Solicited symptoms of reactogenicity and adverse events will be assessed on vaccination day and daily during the 7 days following each Vaccination Visit using either electronic or paper symptoms diaries, depending on study participant preference. Quality of life data will be collected using electronic or paper diaries on day of Vaccination Visit 1 and daily during the 7 days following the visit. Serious adverse events and adverse events of special interest will be collected throughout the duration of the study. Participants are followed through Day 121. Serum samples from participants will be collected for determination of SARS-CoV-2 seropositivity at baseline. Serum samples will be taken throughout the study to determine IIV4 and COVID-19 vaccine immunogenicity and for potential future studies. Type: Interventional Start Date: Oct 2021 |
|
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions i1
Pfizer
Immunocompromised
Immunosuppressed
Covid-19
SARS-COV-2
SARS-COV-2 Infection
This retrospective study will evaluate characteristics, vaccine utilization and outcomes
among subjects with immunocompromising conditions that received COVID-19 vaccination. expand
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination. Type: Observational Start Date: Aug 2021 |
|
Recovery of Respiratory System in COVID-19 Patients
Mayo Clinic
Covid19
The purpose of this study is to determine the effects of the clinical course of treatment
as well as long-term symptoms of COVID-19 on respiratory function, exercise capacity, and
quality of life. expand
The purpose of this study is to determine the effects of the clinical course of treatment as well as long-term symptoms of COVID-19 on respiratory function, exercise capacity, and quality of life. Type: Observational Start Date: Feb 2022 |
|
Acupuncture Therapy for COVID-Related Olfactory Loss
Mayo Clinic
Olfactory Dysfunction
COVID-19
This study is looking at the role of acupuncture as a treatment for olfactory dysfunction
in patients who tested positive for COVID-19. expand
This study is looking at the role of acupuncture as a treatment for olfactory dysfunction in patients who tested positive for COVID-19. Type: Interventional Start Date: Dec 2021 |
|
A Retrospective Study of COVID-19 Treatments
ProgenaBiome
Covid19
COVID-19 Pneumonia
COVID-19 Respiratory Infection
COVID-19 Acute Bronchitis
COVID-19 Acute Respiratory Distress Syndrome
Surveys administered to subjects who have recovered from COVID-19 to assess how effective
their treatment was. expand
Surveys administered to subjects who have recovered from COVID-19 to assess how effective their treatment was. Type: Observational Start Date: Feb 2021 |
|
Optimization of a New Adaptive Intervention to Increase COVID-19 Testing
University of Illinois at Urbana-Champaign
COVID-19 Testing
This study tests an adaptation of the HIV Continuum of Prevention, Care, and Treatment
Framework (CoPCT) for use in tracking COVID-19 testing and follow-up in a medically and
socially vulnerable population. This study uses an integrated research collaborative
framework that facilitates dialogue amo1 expand
This study tests an adaptation of the HIV Continuum of Prevention, Care, and Treatment Framework (CoPCT) for use in tracking COVID-19 testing and follow-up in a medically and socially vulnerable population. This study uses an integrated research collaborative framework that facilitates dialogue among researchers, community members, and service providers as a tool for optimizing the adaptive intervention and will take place at the North Jersey Community Research Initiative (NJCRI) Type: Interventional Start Date: Feb 2021 |
|
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
National Institute of Allergy and Infectious Diseases (NIAID)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Multisystem Inflammatory Syndrome in Children (MIS-C)
Coronavirus Disease 2019 (COVID-19)
The primary objectives of this study are:
- To determine the proportion of children with Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) related death, rehospitalization or major complications
after infection with SARS-CoV-2 and/or Multisystem Inflammatory Syndrome in Chi1 expand
The primary objectives of this study are: - To determine the proportion of children with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) related death, rehospitalization or major complications after infection with SARS-CoV-2 and/or Multisystem Inflammatory Syndrome in Children (MIS-C), and - To determine immunologic mechanisms and immune signatures associated with disease spectrum and subsequent clinical course during the year of follow-up. Type: Observational Start Date: Nov 2020 |
|
Mouth Rinses for Inactivation of COVID-19
University of North Carolina, Chapel Hill
Covid19
Coronavirus Infection
SARS-CoV-2 Infection
Randomized, double-blind prospective trial to test the efficacy and acceptability of
therapeutic, antiseptic mouth rinses to inactivate severe acute respiratory syndrome
coronavirus (SARS-CoV-2) in saliva of COVID-19 positive patients aged 18-65 years old.
All mouthrinses are commercially available1 expand
Randomized, double-blind prospective trial to test the efficacy and acceptability of therapeutic, antiseptic mouth rinses to inactivate severe acute respiratory syndrome coronavirus (SARS-CoV-2) in saliva of COVID-19 positive patients aged 18-65 years old. All mouthrinses are commercially available and will be used according to on-label instructions. Patients will be randomized to a mouthrinse and will be asked to give a saliva sample immediately before and after a one minute mouthwash. Saliva samples will be collected from patients at 15 minute intervals thereafter up to an hour (15, 30, 45 and 60 minutes). The samples will be stored and used for real-time reverse transcription polymerase chain reaction (RT-PCR) detection of viral SARS-CoV-2 RNA and viral infectivity assays. Patients will also complete a short-survey on the taste and experience of using the mouthwash. This study involves 480 subject participants and one, 75-90 minute visit. Type: Interventional Start Date: Dec 2020 |
|
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
AstraZeneca
COVID-19
SARS-CoV-2
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for
the prevention of COVID-19. expand
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19. Type: Interventional Start Date: Aug 2020 |
|
BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients
Humanetics Corporation
COVID-19
Long COVID
Pulmonary Fibrosis
Post-acute Respiratory Complications of COVID-19
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the
safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung
function in patients that were hospitalized for severe COVID-19-related illness and
continue to experience post-acute respira1 expand
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe COVID-19-related illness and continue to experience post-acute respiratory complications associated with Long-COVID after discharge. Patients will be randomized 1:1 to receive BIO 300 or placebo. Type: Interventional Start Date: Nov 2020 |
|
Leflunomide in Mild COVID-19 Patients
University of Chicago
COVID-19
This study aims to examine the tolerability of high dose of leflunomide in patients with
COVID-19 who are being managed in the outpatient setting. expand
This study aims to examine the tolerability of high dose of leflunomide in patients with COVID-19 who are being managed in the outpatient setting. Type: Interventional Start Date: May 2020 |
|
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adu1
ModernaTX, Inc.
SARS-CoV-2
Influenza
The primary goal of this study is to evaluate the safety, reactogenicity, and
immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines
and to the individual vaccines alone in healthy participants. expand
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants. Type: Interventional Start Date: May 2022 |
|
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
Vir Biotechnology, Inc.
Covid19
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab
versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19.
In the safety substudy, the aim was to evaluate the safety and tolerability of sotrovimab
across a single ascending dose le1 expand
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19. In the safety substudy, the aim was to evaluate the safety and tolerability of sotrovimab across a single ascending dose level and over different infusion times when given for the treatment of mild/moderate COVID-19 to participants at high risk of disease progression Main study was completed successfully. The safety sub-study was discontinued early in the context of evolving variants with increased fold changes in the in vitro half maximal inhibitory concentration (IC50) and uncertainty in the clinical relevance of these changes. Type: Interventional Start Date: Jun 2021 |
|
Hyperbaric Oxygen for Long COVID-19 Pulmonary Sequela
Peter Lindholm
Covid19
This is a pilot study in 24 subjects where half will be randomized to 10 treatments with
hyperbaric oxygen (HBO). It will primarily study pulmonary sequelae with imaging and
physiological measurements (low dose chest computer tomography (CT),
Ventilation/perfusion with magnetic resonance imaging (V1 expand
This is a pilot study in 24 subjects where half will be randomized to 10 treatments with hyperbaric oxygen (HBO). It will primarily study pulmonary sequelae with imaging and physiological measurements (low dose chest computer tomography (CT), Ventilation/perfusion with magnetic resonance imaging (VA/Q MRI), cardiopulmonary exercise testing with pulse oximetry (SpO2) and spirometry including diffusion capacity for carbon monoxide (DLCO). The target patient group will be previously healthy whom have had covid-19 with lingering symptoms past 12 weeks of recovery from the acute phase. Type: Interventional Start Date: Nov 2021 |
|
Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
Octapharma
Covid-19
This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to
evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in
patients with severe Coronavirus disease expand
This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in patients with severe Coronavirus disease Type: Interventional Start Date: Jun 2020 |
|
CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
Washington University School of Medicine
COVID 19
The objective of CROWN CORONATION is the prevention of symptomatic COVID-19 by using
combinations of approved and safe repurposed interventions, with complementary mechanisms
of action. expand
The objective of CROWN CORONATION is the prevention of symptomatic COVID-19 by using combinations of approved and safe repurposed interventions, with complementary mechanisms of action. Type: Interventional Start Date: Sep 2020 |
|
Protecting Our Community: COVID-19 Testing
Montana State University
SARS-CoV-2
Covid19
The COVID-19 pandemic has disproportionately affected American Indian (AI) and Latino
communities, and these groups also have increased risk of poor prognosis due to high
rates of chronic disease such as diabetes, cardiovascular disease, and cancer. In the
northwestern United States, AI and Latino1 expand
The COVID-19 pandemic has disproportionately affected American Indian (AI) and Latino communities, and these groups also have increased risk of poor prognosis due to high rates of chronic disease such as diabetes, cardiovascular disease, and cancer. In the northwestern United States, AI and Latino communities already face significant disparities in health care access, which have been further exacerbated by the COVID-19 pandemic. In the proposed study, Protecting Our Community: A Pragmatic Randomized Trial of Home-Based COVID Testing with Native American and Latino Communities, the investigators will leverage our long-term community-based participatory research partnerships to test the hypothesis that home-based testing will be feasible, impactful, and better-accepted using active delivery of test kits by trusted community health educators in two vulnerable, high-risk rural communities. Our two long-term partner communities are the Flathead Indian Reservation of the Confederated Salish and Kootenai Tribes in Montana, and the Yakima Valley of Washington, a large Latino community. The investigators will determine the cultural, social, behavioral, and economic barriers to home-based SARS-CoV-2 testing; culturally adapt and enhance home-testing educational materials and create home-testing instructional graphics and YouTube videos; conduct a 2-arm pragmatic randomized trial of active (delivered by community health educator) vs. passive (without community health educator) home-based testing kits (n = 200/community) for testing completion; and create a model for community-driven testing protocols that can have significant impact for increasing home-based testing uptake among AI and Latino communities nationally. This work will enable underserved AI and Latino communities to take full advantage of the coming wave of rapid point-of-care home tests and decrease the significant impact of COVID-19 in their communities. Type: Interventional Start Date: Apr 2021 |
|
Studying Students at Risk for COVID-19
University of Michigan
Covid19
The goal of this longitudinal observational study is to learn about how the COVID-19 has
impacted and continues to impact students at the University of Michigan. We hope to
determine whether a combination of (1) continuous heart rate obtained from wearable
devices, (2) self-reported data from surve1 expand
The goal of this longitudinal observational study is to learn about how the COVID-19 has impacted and continues to impact students at the University of Michigan. We hope to determine whether a combination of (1) continuous heart rate obtained from wearable devices, (2) self-reported data from surveys and symptom logs, and (3) saliva samples can be used to help students self-monitor for infection and eventually be able to create a predictive model to detect illness early. Type: Observational Start Date: Sep 2020 |